Pharmacokinetics-pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612

被引：0
|
作者：
Birnberg, T. [1 ]
Adar, L. [1 ]
Poewe, W. [2 ]
Nyholm, D. [3 ]
Bjornsson, M. [4 ]
Karlsson, M. [4 ]
机构：
[1] NeuroDerm, Rehovot, Israel
[2] Med Univ Innsbruck, Innsbruck, Austria
[3] Uppsala Univ, Uppsala, Sweden
[4] Pharmetheus, Uppsala, Sweden
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2022年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-363
引用
收藏
页码：608 / 608
页数：1
相关论文
共 50 条
  • [21] Continuous Subcutaneous Levodopa/Carbidopa Infusion with ND0612 For Parkinson's Disease: Three-year Data from the Openlabel BeyoND Study
    Poewe, W.
    Ellenbogen, A.
    Stocchi, F.
    Adar, L.
    Salin, L.
    Case, R.
    Yardeni, T.
    Giladi, N.
    MOVEMENT DISORDERS, 2023, 38 : S46 - S46
  • [22] Long-Term Efficacy of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612) for Motor Fluctuations in Parkinson's disease (PD)
    Espay, A.
    Pahwa, R.
    Ellenbogen, A.
    Stocchi, F.
    Giladi, N.
    Salin, L.
    Sasson, N.
    Pereira, J.
    Rascol, O.
    MOVEMENT DISORDERS, 2024, 39 : S301 - S301
  • [23] LONG-TERM SAFETY OF CONTINUOUS LEVODOPA/CARBIDOPA INFUSION WITH ND0612: RESULTS FROM THE ONGOING BEYOND STUDY
    Poewe, W.
    Stocchi, F.
    Sopromadze, S.
    Adar, L.
    Sasson, N.
    Yardeni, T.
    Giladi, N.
    PARKINSONISM & RELATED DISORDERS, 2023, 113 : 46 - 46
  • [24] Long-term safety of continuous levodopa/carbidopa infusion with ND0612: Results from the ongoing BeyoND study
    Poewe, W.
    Stocchi, F.
    Sopromadze, S.
    Adar, L.
    Sasson, N.
    Yardeni, T.
    Giladi, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 181 - 181
  • [25] Pharmacokinetic and safety characterisation of carbidopa/levodopa subcutaneous infusion (ND0612): Phase I studies in healthy volunteers and patients with fluctuating Parkinson's disease
    Lewitt, P.
    Caraco, Y.
    Adar, L.
    Oren, S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 514 - 514
  • [26] CONTINUOUS SUBCUTANEOUS LEVODOPA/CARBIDOPA INFUSION (ND0612) FOR PATIENTS WITH PARKINSON'S DISEASE AND MOTOR FLUCTUATIONS: A PHASE 3, ACTIVE-CONTROLLED STUDY (BOUNDLESS)
    Stocchi, F.
    Espay, A.
    Albanese, A.
    Ellenbogen, A.
    Ferreira, J. J.
    Giladi, N.
    Gurevich, T.
    Hassin-Baer, S.
    Hernandez-Vara, J.
    Isaacson, S.
    Kieburtz, K.
    LeWitt, P.
    Lopez-Manzanares, L.
    Olanow, C. W.
    Pahwa, R.
    Poewe, W.
    Sarva, H.
    Yardeni, T.
    Adar, L.
    Lopes, N.
    Sasson, N.
    Case, R.
    Rascol, O.
    PARKINSONISM & RELATED DISORDERS, 2024, 122
  • [27] ND0612, a novel liquid formulation of levodopa/carbidopa for subcutaneous infusion in patients with Parkinson's disease achieves stable levodopa plasma levels when administered in low and high doses
    Giladi, Nir
    Caraco, Yoseph
    Gurevich, Tanya
    Djaldetti, Ruth
    Adar, Liat
    Cohen, Yael
    Minei, Tamar Rachmilewitz
    Oren, Sheila
    NEUROLOGY, 2017, 88
  • [28] ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study
    Giladi, Nir
    Gurevich, Tanya
    Djaldetti, Ruth
    Adar, Liat
    Case, Ryan
    Leibman-Barak, Shelly
    Sasson, Nissim
    Caraco, Yoseph
    PARKINSONISM & RELATED DISORDERS, 2021, 91 : 139 - 145
  • [29] Pharmacokinetic analysis of levodopa and carbidopa following subcutaneous infusion: A population pharmacokinetics model
    Birnberg, T.
    Adar, L.
    Perlstein, I.
    Smania, G.
    Bjornsson, M.
    Jonnson, N.
    Karlsson, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 235 - 235
  • [30] Pharmacokinetic analysis of levodopa and carbidopa following subcutaneous infusion: A population pharmacokinetics model
    Birnberg, Tal
    Smania, Giovanni
    Bjornsson, Marcus
    Jonsson, Niclas
    Case, Ryan
    Oren, Sheila
    Adar, Liat
    Karlsson, Mats
    NEUROLOGY, 2021, 96 (15)
12345